About Alkermes

Leadership

Collaborations

Other Information

Message From the CEO

Message from CEO

At Alkermes, we have a steadfast commitment to develop innovative medicines based on our imaginative science and proven technologies.  We are inspired by real patient needs as we develop products to help patients and physicians better manage diseases.

We are in an exciting phase of growth that few biotechnology companies achieve, with our diversified portfolio of commercial products and an exciting late-stage pipeline.  We are moving ahead with global capabilities, an established approach to innovation, world-class manufacturing, financial strength, and our experienced and dedicated people.

Our track record for successful drug development is evident from the more than 20 marketed drugs that use our proprietary technologies, and perhaps most clearly exemplified by the five key commercial products propelling our growth.  These are breakthrough products in major disease areas, such as schizophrenia, addiction, and multiple sclerosis.

In addition, we have a pipeline of proprietary drug candidates that fit our product paradigm to address unique therapeutic needs and improve outcomes for patients.  Our rich pipeline demonstrates our leadership in drug development for central nervous system (CNS) diseases, a therapeutic area where we have a well-established past and a promise for delivering new products.

We couldn’t be more enthusiastic and optimistic about the future growth of Alkermes.  Our R&D approach is an engine for innovation, as our people and our proven technologies continue to be a source of original product ideas.  Our deep scientific, drug development and manufacturing capabilities provide us with competitive advantages as we continue our pursuit of patient-inspired products ourselves and with pharmaceutical partners.

We welcome your interest in our company.

Sincerely,

Richard F. Pops, Chief Executive Officer